Back to search results

Corrie Lipids Digital Health Program for High Cholesterol

This study is testing the Corrie Lipids Digital Health Program, a new digital health tool for adults with high cholesterol (uncontrolled LDL-C) and a high risk for heart and blood vessel disease (ASCVD). The program includes a smartphone app to help you track your cholesterol, remember medications, and learn more about your condition. It also provides education and support for your doctors. Researchers want to see if this program helps people reach their cholesterol goals and how well it is used. You may be able to join if you are 18 or older, have uncontrolled LDL-C, and at least one major cardiovascular risk factor. The study aims to enroll about 1,000 participants. The current recruitment status is unclear.

Study design
This is an interventional study involving about 1,000 participants. It is designed to evaluate the effectiveness and implementation of the Corrie Lipids Digital Health Program.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months to assess their LDL-C goals and for 6 months to track app engagement.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07478887

Impact of the Corrie Lipids Digital Health Program on Lipid Optimization

Recruiting
NAAges 18+InterventionalSupportive care
Johns Hopkins University
~1,000 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:Corrie Lipids Digital Health Program

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants achieving guideline-based LDL-C goals
Measured over 6 months, 12 months
+1 more outcome measured

Conditions

Cardiovascular Risk
LDL-C
Lipids
Digital Health
Implementation Science

Explore related trials

Cardiovascular DisorderDiabetes MellitusHypercholesterolemia

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Stacey Schott, MD, MPH · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Francoise Marvel, MD
[email protected]
410-502-0469
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years
Uncontrolled LDL-C per AHA/ACC guidelines
At least 1 major cardiovascular risk factor, including: high risk for ASCVD (individuals who meet criteria for Lipid-Lowering Therapy (LLT) based on ASCVD risk assessment using the most up-to-date guidelines), known ASCVD or subclinical ASCVD based on imaging, clinically diagnosed familial hypercholesterolemia or LDL-C ≥190 mg/dL, diabetes mellitus, history of statin-associated side effects
Has a primary care physician and/or cardiologist who can prescribe lipid therapy
Owns a smartphone and agrees to the End User License Agreement to use the digital health app
Provided informed consent before initiation of study-specific activities

Exclusion

Motor, cognitive, auditory, or visual impairment limiting technology use
Does not speak English
Malignancy (except nonmelanoma skin cancers or cervical or breast ductal carcinoma in situ within the previous 5 years)
Pregnancy (positive pregnancy test, highly sensitive urine or serum), plan to become pregnant or donate eggs, breastfeeding or plan to breastfeed
Likely to not be available to comply with all required study procedures to the best of the patient's and investigator's knowledge
History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion

What this trial measures

  • Percentage of participants achieving guideline-based LDL-C goals6 months, 12 months

    LDL-C Goal Achievement assessed 6 months after enrollment in the Corrie Lipids program

  • Percentage of participants who download and engage with the Corrie app6 months

    Patient Engagement With the App defined as downloading and completing an educational article or video among those who were offered the app.